

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN:L70101WB1982PLC121196

Reg. Office: 6TH FLOOR, PREMISES 602, MAHAVIR APARTMENT 2, ASHUTOSH MUKHERJEE ROAD KOLKATA-700020

Email: shreeganeshbiotechindiaLtd@gmail.com

Date: 13.11.2021

To,
Listing Department,
BSE Limited,
P J Tower, Dalal
Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock
Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock Exchange of
India Limited
Vibgyor Towers, 4th floor, Plot No
C 62, Opp. Trident Hotel Bandra
Kurla Complex, Bandra (E),
Mumbai – 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code: SHREEGANES

Dear Sir/Madam,

Sub: Un-Audited Financial Result quarter and half year ended on 30th September 2021 pursuant to Regulation 33 of the SEBI (LODR) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Saturday November 13, 2021 at the Registered Office of the Company and transacted the following major businesses:

1. Approval of Un-audited financial results for quarter and half year ended as on 30th September, 2021.
2. The Registered office of the company is shifted to Cubicle No:126,3/2 ,75C,PARK STREET,3RD FLOOR ,KAMDHENU BUILDING ,KOLKATA-700016 w.e.f 13.11.2021

Kindly take the same on your record and oblige.

Thanking You.

Yours faithfully,

For, SHREE GANESH BIO-TECH (INDIA) LIMITED

Director/Authorised Signatory



Shree Ganesh Biotech (India) Ltd


CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindia@gmail.com

Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2021

Sl no.	Particulars	Quarter Ended			Six Months Ended		(Rs. In lacs)
		30-Sep-21	30-Jun-21	30-Sep-20	30-Sep-21	30-Sep-20	Year Ended 31 Mar 2021
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	INCOME						
(a)	Revenue From Operation	1,795.99	1,551.61	-	3,347.60	11.35	1,721.38
(b)	Other Income	0.19	4.64	-	4.83	-	-
	Total Income from Operations (Net)	1,796.18	1,556.25	-	3,352.43	11.35	1,721.38
2	EXPENSES						
(a)	Cost of material consumed	1,696.44	1,485.91	-	3,182.35	7.70	1,632.98
(b)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	9.59	(9.59)	-	-	-	-
(c)	Employee benefit expense	6.06	5.90	0.95	11.96	1.94	7.92
(d)	Finance Costs	-	-	-	-	-	0.04
(e)	Depreciation and amortization expense	-	-	-	-	-	0.06
(f)	Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	1.68	5.81	2.58	7.49	9.66	9.67
	Total Expenses	1,713.77	1,488.03	3.53	3,201.80	19.30	1,650.67
3	Profit / (Loss) from operations before exceptional items Tax (1-2)	82.41	68.22	(3.53)	150.63	(7.95)	70.71
4	Exceptional Items	-	-	-	-	-	(27.90)
5	Profit / (Loss) before Tax (3 ± 4)	82.41	68.22	(3.53)	150.63	(7.95)	42.81
6	Tax Expense	-	-	-	-	-	11.13
7	Net Profit / (Loss) after Tax (5 - 6)	82.41	68.22	(3.53)	150.63	(7.95)	31.68
8	Other Comprehensive Income (net of tax)	-	-	-	-	-	-
9	Total Comprehensive Income for the period (7 ± 8)	82.41	68.22	(3.53)	150.63	(7.95)	31.68
10	Paid-up equity share capital (Face Value of Rs.10/- each)	1,993.12	1,993.12	1,993.12	1,993.12	1,993.12	1,993.12
11	Other Equity	-	-	-	-	-	3,786.09
12	Earnings Per Share (of Rs. 10/- each) (not annualised):						
(a)	Basic	0.41	0.34	(0.02)	0.76	(0.04)	0.16
(b)	Diluted	0.41	0.34	(0.02)	0.76	(0.04)	0.16



Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindia@gmail.com

(Rs. in Lakhs)

Standalone Statement of Assets and Liabilities		As at 30th September, 2021	As at 31st March, 2021
	Particulars	Un-Audited	Audited
A	ASSETS		
1	Non-current assets		
	Property, plant and equipment	0.40	0.40
	Capital work-in-progress	-	-
	Other intangible assets	-	-
	Investments in subsidiaries, associates and joint ventures	-	-
	Financial assets		
	Investments	323.16	306.01
	Loans	4,511.15	4,315.79
	Other financial assets	-	-
	Income Tax assets (net)	-	-
	Deferred tax assets (net)	-	-
	Other non-current assets	-	-
	Sub-total - Non-Current Assets	4,834.71	4,622.20
2	Current assets		
	Inventories	-	-
	Financial assets		
	Investments	-	-
	Trade receivables	4,684.77	2,833.93
	Cash and cash equivalents	2.21	2.22
	Bank balances other than Cash and Cash equivalents above	0.14	0.20
	Loans, Current	-	-
	Other financial assets	-	-
	Other current assets	4.17	4.17
	Assets classified as held for sale	-	-
	Sub-total - Current Assets	4,691.29	2,840.52
	TOTAL - ASSETS	9,526.00	7,462.72
B	EQUITY AND LIABILITIES		
1	Equity		
	Equity Share capital	1,993.12	1,993.12
	Other equity	3,936.72	3,786.09
	Sub-total - Shareholders' funds	5,929.84	5,779.21
2	LIABILITIES		
	Non-current liabilities		
	Financial liabilities		
	Borrowings, non-Current	19.03	19.03
	Provisions	-	-
	Income tax liabilities (net)	-	-
	Other non-current liabilities	-	-
	Sub-total - Non-current liabilities	19.03	19.03
3	Current liabilities		
	Financial liabilities		
	Borrowings, Current	-	-
	Trade payables, Current	3,561.46	1,652.82
	Other financial liabilities	-	-
	Other current liabilities	4.54	0.53
	Provisions	11.13	11.13
	Current tax liabilities (net)	-	-
	Sub-total - Current liabilities	3,577.13	1,664.48
	TOTAL - EQUITY AND LIABILITIES	9,526.00	7,462.72



Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

Email:- shreeganeshbiotechindia@gmail.com

Notes:

- 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 13, 2021.
- 2 The Statutory Auditors have carried out a limited review of the above financial result.
- 3 Company has only one segment and hence no separate segment result has been given.
- 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.
- 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

By order of the Board
For, Shree Ganesh Biotech (India) Ltd

Place : Kolkata

Date : 13th November, 2021

Director/Compliance Officer



Shree Ganesh Biotech (India) Ltd

CIN:- L70101WB1982PLC121196

Regd. Office: 6th Floor, Premises - 602, Mahavir Apartment, 2, Ashutosh Mukherjee Road, Kolkata - 700020

STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2021

(Rs. in Lakhs, unless otherwise stated)

Particulars	30.09.2021	30.09.2020
	Rupees	Rupees
A. CASH FLOW FROM OPERATING ACTIVITIES:		
Profit before tax	150.63	7.95
Adjustment For:		
Share of (profit)/loss from investment in partnership firm	-	-
Depreciation/amortization on continuing operation	-	-
Interest expenses	-	-
Operating profit before working capital changes	150.63	7.95
Movement in Working Capital :		
Increase/(decrease) in Inventory	-	-
Increase/(decrease) in Trade receivables	1,850.84	5.79
Increase/(decrease) in Short Term Loan & Advances	-	-
Increase/(decrease) in Current Liabilities	4.01	-
Increase/(decrease) in Trade Payable	1,908.64	11.89
Increase/(decrease) in Other Current Assets	-	-
Direct taxes paid (net of refunds)	-	-
Net Cash Flow from Operating Activities(A)	212.44	1.85
B. CASH FLOW FROM INVESTING ACTIVITIES		
Investments /withdrawl in Partnership Firm	17.15	-
Purchase / Sale of Fixed Assets	-	-
Increase/(decrease) in Long Term Loan & Advances	195.36	1.33
Net Cash Flow from Investing Activities(B)	212.51	1.33
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceed (Repayment) from long term borrowing	-	-
Proceed (Repayment) from short term borrowing	-	-
Proceed from Preferential Warrants	-	-
Net Cash Flow from Financing Activities(C)	-	-
Net increase/(decrease) in cash & cash equivalents(A+B+C)	0.07	0.52
Cash and Cash equivalents (Opening Balance)	2.42	1.79
Cash and Cash equivalents (Closing Balance)	2.35	1.27

Previous year figure have been regrouped/ reclassified wherever necessary

As per our report of even date

For, BIPIN & CO.

Chartered Accountants

FRN: 101509 W

Amrit Shah

CA AMIT SHAH

Partner

M. No: 126337

Place: VADODARA

Date : 13th November, 2021



For and on Behalf of the Board



Place: KOLKATA

Date : 13th November, 2021



**INDEPENDENT AUDITORS' REVIEW REPORT ON THE STANDALONE UNAUDITED FINANCIAL RESULTS FOR
QUARTER AND HALF YEAR ENDED SEPTEMBER 30, 2021**

To
The Board of Directors of
Shree Ganesh Biotech (India) Ltd
Kolkata


We have reviewed the unaudited standalone financial results of Shree Ganesh Biotech (India) Ltd ("the Company") for the quarter ended September 30, 2021 which are included in the accompanying 'Statement of Standalone Unaudited Financial Results for the quarter ended September 30, 2021 and notes thereon (together referred to as the 'Standalone Statement'). The Standalone Statement has been prepared by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the Listing Regulations, 2015).

This Standalone Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Standalone Statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standard of Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the Standalone Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other recognized accounting practices generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509W


CA Amit Shah (Partner)
M. No.: 126337
UDIN: 21126337AAAAHH1140
Place: Vadodara
Date: 13.11.2021

